Minerva Surgical, Inc.
UTRS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.42 | 0.13 | 0.00 |
| FCF Yield | -554.77% | -15.59% | -6.91% | -11.99% |
| EV / EBITDA | -1.95 | 163.42 | 320.97 | -12.22 |
| Quality | ||||
| ROIC | -54.33% | -31.52% | -25.28% | -62.42% |
| Gross Margin | 54.17% | 58.58% | 50.62% | 45.38% |
| Cash Conversion Ratio | 1.04 | 1.04 | 0.67 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.02% | 26.06% | 3,355,019.52% | 2,962,851.77% |
| Free Cash Flow Growth | -55.21% | -80.90% | 36.58% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.63 | -1.49 | 97.35 | -2.76 |
| Interest Coverage | -9.59 | -2.49 | -1.27 | -1.12 |
| Efficiency | ||||
| Inventory Turnover | 1.37 | 1.38 | 1.83 | 2.99 |
| Cash Conversion Cycle | 274.97 | 254.95 | 212.02 | 69.54 |